CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 578045-578116 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/2008f024274c53b0de1276f4047a6a641813fd98","sourcedb":"CORD-19","sourceid":"2008f024274c53b0de1276f4047a6a641813fd98","text":"MLT can be considered in immunotherapy as an adjunct to IL-2 treatment.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T39397","span":{"begin":0,"end":71},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T39397","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T344","span":{"begin":0,"end":71},"obj":"Sentence"}],"attributes":[{"subj":"T344","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5467","span":{"begin":0,"end":3},"obj":"Disease"}],"attributes":[{"id":"A5467","pred":"mondo_id","subj":"T5467","obj":"http://purl.obolibrary.org/obo/MONDO_0018735"},{"subj":"T5467","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93eca5","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ec939a"},{"id":"CORD-19-PD-MONDO","color":"#93b4ec"}]}]}}